Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies, Inc. announced that on December 3, 2025, its Compensation Committee granted inducement stock options to two new employees totaling 212,000 shares of the company’s common stock under its 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to the closing share price on the grant date, carry a 10-year term, and vest over four years with 25 % vesting after the first year and the remainder vesting monthly over the next 36 months. This grant is part of Taysha’s ongoing efforts to attract and retain key talent as it advances its AAV-based gene therapy programs for severe monogenic diseases of the central nervous system. 

Learn More